Market Overview

Recap: Eagle Pharmaceuticals Q2 Earnings

Share:

Shares of Eagle Pharmaceuticals (NASDAQ:EGRX) were flat in pre-market trading after the company reported Q2 results.

Quarterly Results

Earnings per share decreased 32.14% year over year to $0.57, which beat the estimate of $0.26.

Revenue of $41,938,000 decreased by 26.04% year over year, which missed the estimate of $42,280,000.

Outlook

Earnings guidance hasn't been issued by the company for now.

Eagle Pharmaceuticals hasn't issued any revenue guidance for the time being.

Conference Call Details

Date: Aug 10, 2020

Time: 08:30 AM

ET Webcast URL: https://event.on24.com/eventRegistration/EventLobbyServlet?target=reg20.jsp&referrer=https%3A%2F%2Finvestor.eagleus.com%2Fevents-and-presentations%2Fdefault.aspx&eventid=2402260&sessionid=1&key=0129C521D736B325C69279B72A2EEA31&regTag=&sourcepage=register

Technicals

Company's 52-week high was at $64.94

Company's 52-week low was at $33.80

Price action over last quarter: down 13.26%

Company Description

Eagle Pharmaceuticals Inc is a specialty pharmaceutical company. The company develops and commercializes injectable products in the areas of critical care, orphan diseases, and oncology. Its product portfolio consists of four approved products: Argatroban, Ryanodex, Belrapzo, and Bendeka. The company currently has multiple product candidates in advanced stages of development, and under review for approval by the Food and Drug Administration.

 

Related Articles (EGRX)

View Comments and Join the Discussion!

Posted-In: Earnings News